Estimated Cost-Effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
Faculty Publications
Part of the Pharmacy and Pharmaceutical Sciences Commons
Part of the Pharmacy and Pharmaceutical Sciences Commons